Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics

Therapeutic Delivery

Volumn 2, Issue 7, 2011, Pages 873-889

  Chittasupho, Chuda ^a,b   Siahaan, Teruna J ^a   Vines, Charlotte M ^c   Berkland, Cory ^a,d  

^a UNIVERSITY OF KANSAS   (United States)

^b SRINAKHARINWIROT UNIVERSITY   (Thailand)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^d Department of Pharmaceutical Chemistry ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AUTOANTIBODY; B7 ANTIGEN; BELATACEPT; CD28 ANTIGEN; CHOLINERGIC RECEPTOR; CORTICOSTEROID DERIVATIVE; CYTOKINE; CYTOTOXIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACETUZUMAB; EFALIZUMAB; ETANERCEPT; GALIXIMAB; IMMUNOGLOBULIN; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; IPILIMUMAB; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEMBRANE PROTEIN; METHOTREXATE; NATALIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; RITUXIMAB; THYROTROPIN RECEPTOR; TICILIMUMAB; UNINDEXED DRUG;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B CELL LYMPHOMA; BRAIN INFECTION; BRAIN ISCHEMIA; CELL ADHESION; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; IMMUNOLOGICAL SYNAPSE; IMMUNOREGULATION; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MELANOMA; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 79961177838     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.60     Document Type: Review

References (164)

1. Wraith DC. Therapeutic peptide vaccines for treatment of autoimmune diseases. Immunol. Lett. 122(2), 134-136 (2009).
2. Kindt TJ, Goldsby RA, Osborne BA, Kuby J. Kuby Immunology. WH Freeman, NY, USA (2007).
3. Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: what is the evidence? Lancet 362(9396), 1659-1666 (2003). (Pubitemid 37443537)
4. Larche M, Wraith DC. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat. Med. 11(4 Suppl.), S69-S76 (2005). (Pubitemid 40562306)
5. Balague C, Kunkel SL, Godessart N. Understanding autoimmune disease: new targets for drug discovery. Drug Discov. Today 14(19-20), 926-934 (2009).
6. Stuart RW, Racke MK. Targeting T cell costimulation in autoimmune disease. Exp. Opin. Ther. Targets 6(3), 275-289 (2002). (Pubitemid 34662101)
7. Bucks CM, Katsikis PD. New insights into classical costimulation of CD8+ T cell responses. Adv. Exp. Med. Biol. 633, 91-111 (2009).
8. Ma A, Zhang L, Wang X, Chen H. New look at therapeutic strategies for blocking costimulatory signal in experimental and pre-clinical transplantation. Curr. Drug Saf. 4(2), 155-166 (2009).
9. Ford ML, Larsen CP. Translating costimulation blockade to the clinic: lessons learned from three pathways. Immunol. Rev. 229(1), 294-306 (2009).
10. Feldmann M, Steinman L. Design of effective immunotherapy for human autoimmunity. Nature 435(7042), 612-619 (2005). (Pubitemid 40825501)
11. Woerly G, Lacy P, Younes AB et al. Human eosinophils express and release IL-13 following CD28-dependent activation. J. Leukoc. Biol. 72(4), 769-779 (2002). (Pubitemid 36277849)
12. Woerly G, Roger N, Loiseau S, Dombrowicz D, Capron A, Capron M. Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon gamma): inhibition by immunoglobulin a complexes. J. Exp. Med. 190(4), 487-495 (1999). (Pubitemid 29395377)
13. Dilioglou S, Cruse JM, Lewis RE. Function of CD80 and CD86 on monocyte- and stem cell-derived dendritic cells. Exp. Mol. Pathol. 75(3), 217-227 (2003). (Pubitemid 37373708)
14. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat. Rev. Immunol. 1(3), 220-228 (2001). (Pubitemid 33741960)
15. Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134).Annu. Rev. Immunol. 28, 57-78 (2010).
16. Gottlieb AB, Kang S, Linden KG et al. Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin. Immunol. 111(1), 28-37 (2004). (Pubitemid 38482079)
17. Gottlieb AB, Lebwohl M, Totoritis MC et al. Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody. J. Am. Acad. Dermatol. 47(5), 692-700 (2002). (Pubitemid 35239329)
18. Mease P, Genovese MC, Gladstein G et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, Phase II trial. Arthritis Rheum. 63(4), 939-948 (2011).
19. Sakthivel P. Bench to bedside of CTLA-4: a novel immuno-therapeutic agent for inflammatory disorders. Recent Pat. Inflamm. Allergy Drug Discov. 3(2), 84-95 (2009).
20. Rangel EB. Belatacept in clinical and experimental transplantation - progress and promise. Drugs Today (Barc).46(4), 235-242 (2010).
21. Rostaing L, Massari P, Garcia VD et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized Phase II study. Clin. J. Am. Soc. Nephrol. 6(2), 430-439 (2011).
22. Leonard JP, Friedberg JW, Younes A et al. A Phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann. Oncol. 18(7), 1216-1223 (2007). (Pubitemid 47244369)
23. Wang G, Hu P, Yang J, Shen G, Wu X. The effects of PDL-Ig on collagen-induced arthritis. Rheumatol. In. 31(4), 513-519 (2011).
24. Fife BT, Pauken KE. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann. NY Acad. Sci. 1217, 45-59 (2011).
25. Watson MP, George AJ, Larkin DF. Differential effects of costimulatory pathway modulation on corneal allograft survival. Invest. Ophthalmol. Vis. Sci. 47(8), 3417-3422 (2006). (Pubitemid 351639706)
26. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167-3175 (2010).
27. Benson DM Jr, Bakan CE, Mishra A et al. The PD-1/PDL-1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116(13), 2286-2294 (2010).
28. Kaehler KC, Piel S, Livingstone E, Schilling B, Hauschild A, Schadendorf D. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin. Oncol. 37(5), 485-498 (2010).
29. O'Day SJ, Maio M, Chiarion-Sileni V et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm Phase II study. Ann. Oncol. 21(8), 1712-1717 (2010).
30. Wolchok JD, Neyns B, Linette G et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, Phase 2, dose-ranging study. Lancet Oncol. 11(2), 155-164 (2010).
31. Kirkwood JM, Lorigan P, Hersey P et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin. Cancer Res. 16(3), 1042-1048 (2010).
32. Yong PF, Salzer U, Grimbacher B. The role of costimulation in antibody deficiencies: ICOS and common variable immunodeficiency. Immunol. Rev. 229(1), 101-113 (2009).
33. Frey O, Meisel J, Hutloff A et al. Inducible costimulator (ICOS) blockade inhibits accumulation of polyfunctional T helper 1/T helper 17 cells and mitigates autoimmune arthritis. Ann. Rheum. Dis. 69(8), 1495-1501 (2010).
34. Fujimura J, Takeda K, Kaduka Y et al. Contribution of B7RP-1/ICOS co-stimulation to lethal acute GVHD. Pediatr. Transplant 14(4), 540-548 (2010).
35. Zhang QW, Rabant M, Schenk A, Valujskikh A. ICOS-dependent and -independent functions of memory CD4 T cells in allograft rejection. Am. J. Transplant. 8(3), 497-506 (2008). (Pubitemid 351287530)
36. Taylor PA, Panoskaltsis-Mortari A, Freeman GJ et al. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM).Blood 105(8), 3372-3380 (2005).
37. Pan XC, Guo L, Deng YB et al. Further study of anti-ICOS immunotherapy for rat cardiac allograft rejection. Surg. Today 38(9), 815-825 (2008).
38. Murphy KM, Nelson CA, Sedy JR. Balancing co-stimulation and inhibition with BTLA and HVEM. Nat. Rev. Immunol. 6(9), 671-681 (2006). (Pubitemid 44298216)
39. Watanabe N, Gavrieli M, Sedy JR et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat. Immunol. 4(7), 670-679 (2003). (Pubitemid 36874444)
40. Sedy JR, Gavrieli M, Potter KG et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat. Immunol. 6(1), 90-98 (2005). (Pubitemid 40136700)
41. Truong W, Plester JC, Hancock WW et al. Negative and positive co-signaling with anti-BTLA (PJ196) and CTLA-4-Ig prolongs islet allograft survival. Transplantation 84(10), 1368-1372 (2007). (Pubitemid 351339328)
42. Truong W, Plester JC, Hancock WW et al. Combined coinhibitory and costimulatory modulation with anti-BTLA and CTLA-4-Ig facilitates tolerance in murine islet allografts. Am. J. Transplant. 7(12), 2663-2674 (2007). (Pubitemid 350045772)
43. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 229(1), 152-172 (2009).
44. Law CL, Grewal IS. Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges. Adv. Exp. Med. Biol. 647, 8-36 (2009).
45. Hussein M, Berenson JR, Niesvizky R et al. A Phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 95(5), 845-848 (2010).
46. Advani R, Forero-Torres A, Furman RR et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J. Clin. Oncol. 27(26), 4371-4377 (2009).
47. Khubchandani S, Czuczman MS, Hernandez-Ilizaliturri FJ. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies. Curr. Opin. Investig. Drugs 10(6), 579-587 (2009).
48. Furman RR, Forero-Torres A, Shustov A, Drachman JG. A Phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk. Lymphoma 51(2), 228-235 (2010).
49. Redmond WL, Gough MJ, Charbonneau B, Ratliff TL, Weinberg AD. Defects in the acquisition of CD8 T-cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. J. Immunol. 179(11), 7244-7253 (2007).
50. Weinberg AD. The role of OX40 (CD134) in T-cell memory generation. Adv. Exp. Med. Biol. 684, 57-68 (2010).
51. Sadun RE, Hsu WE, Zhang N et al. Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models. J. Immunother. 31(3), 235-245 (2008). (Pubitemid 351440999)
52. Nohara C, Akiba H, Nakajima A et al. Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells. J. Immunol. 166(3), 2108-2115 (2001). (Pubitemid 32114701)
53. Totsuka T, Kanai T, Uraushihara K et al. Therapeutic effect of anti-OX40L and anti-TNF-a mAbs in a murine model of chronic colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 284(4), G595-603 (2003). (Pubitemid 36343209)
54. Yoshioka T, Nakajima A, Akiba H et al. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur. J. Immunol. 30(10), 2815-2823 (2000).
55. Huang L, Ji W, Zhou WF, Shi Q, Chen XY, Hu YM. Effects of costimulatory pathway OX40/OX40L on the pathogenesis of allergic asthma in mice. Zhonghua Er Ke Za Zhi 44(6), 455-458 (2006).
56. Pakala SV, Bansal-Pakala P, Halteman BS, Croft M. Prevention of diabetes in NOD mice at a late stage by targeting OX40/OX40 ligand interactions. Eur. J. Immunol. 34(11), 3039-3046 (2004). (Pubitemid 39549383)
57. Hwang H, Lee S, Lee WH, Lee HJ, Suk K. Stimulation of glucocorticoid-induced tumor necrosis factor receptor family-related protein ligand (GITRL) induces inflammatory activation of microglia in culture. J. Neurosci. Res. 88(10), 2188-2196 (2010).
58. Nocentini G, Riccardi C. GITR: a modulator of immune response and inflammation. Adv. Exp. Med. Biol. 647, 156-173 (2009).
59. Zhou P, Qiu J, L'Italien L et al. Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody. J. Immunother. 33(8), 789-797 (2010).
60. Cote AL, Zhang P, O'Sullivan JA et al. Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T-cell responses to tumor-specific antigens. J. Immunol. 186(1), 275-283 (2010).
61. Kim JI, Sonawane SB, Lee MK et al. Blockade of GITR-GITRL interaction maintains Treg function to prolong allograft survival. Eur. J. Immunol. 40(5), 1369-1374 (2010).
62. Nocentini G, Cuzzocrea S, Genovese T et al. Glucocorticoid-induced tumor necrosis factor receptor-related (GITR)-Fc fusion protein inhibits GITR triggering and protects from the inflammatory response after spinal cord injury. Mol. Pharmacol. 73(6), 1610-1621 (2008). (Pubitemid 351724350)
63. You S, Poulton L, Cobbold S et al. Key role of the GITR/GITRLigand pathway in the development of murine autoimmune diabetes: a potential therapeutic target. PLoS One 4(11), e7848 (2009).
64. Boursalian TE, McEarchern JA, Law CL, Grewal IS. Targeting CD70 for human therapeutic use. Adv. Exp. Med. Biol. 647, 108-119 (2009).
65. Agarwal A, Newell KA. The role of positive costimulatory molecules in transplantation and tolerance. Curr. Opin. Organ Transplant 13(4), 366-372 (2008).
66. Denoeud J, Moser M. Role of CD27/CD70 pathway of activation in immunity and tolerance. J. Leukoc. Biol. 89(2), 195-203 (2010).
67. Roberts DJ, Franklin NA, Kingeter LM et al. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8+ T cells. J. Immunother. 33(8), 769-779 (2010).
68. McEarchern JA, Oflazoglu E, Francisco L et al. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood 109(3), 1185-1192 (2007). (Pubitemid 46220667)
69. Oflazoglu E, Boursalian TE, Zeng W et al. Blocking of CD27-CD70 pathway by anti-CD70 antibody ameliorates joint disease in murine collagen-induced arthritis. J. Immunol. 183(6), 3770-3777 (2009).
70. Yanagisawa S, Takeichi N, Kaneyama T et al. Effects of anti-CD70 mAb on Theiler's murine encephalomyelitis virus-induced demyelinating disease. Brain Res. 1317, 236-245 (2010).
71. Wang J, Fu YX. The role of LIGHT in T cell-mediated immunity. Immunol. Res. 30(2), 201-214 (2004). (Pubitemid 39425343)
72. Wang H, McCann FE, Gordan JD et al. ADAP-SLP-76 binding differentially regulates supramolecular activation cluster (SMAC) formation relative to T cell-APC conjugation. J. Exp. Med. 200(8), 1063-1074 (2004). (Pubitemid 39431130)
73. Wu Q, Fu YX, Sontheimer RD. Blockade of lymphotoxin signaling inhibits the clinical expression of murine graft-versus-host skin disease. J. Immunol. 172(3), 1630-1636 (2004). (Pubitemid 38116810)
74. Xu Y, Flies AS, Flies DB et al. Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease. Blood 109(9), 4097-4104 (2007). (Pubitemid 46641766)
75. Ye Q, Fraser CC, Gao W et al. Modulation of LIGHT-HVEM costimulation prolongs cardiac allograft survival. J. Exp. Med. 195(6), 795-800 (2002). (Pubitemid 34259724)
76. Melero I, Murillo O, Dubrot J, Hervas- Stubbs S, Perez-Gracia JL. Multi-layered action mechanisms of CD137 (4-1BB)- targeted immunotherapies. Trends Pharmacol. Sci. 29(8), 383-390 (2008).
77. Lynch DH. The promise of 4-1BB (CD137)- mediated immunomodulation and the immunotherapy of cancer. Immunol. Rev. 222, 277-286 (2008). (Pubitemid 351430383)
78. Imai Y, Shimaoka M, Kurokawa M. Essential roles of VLA-4 in the hematopoietic system. Int. J. Hematol. 91(4), 569-575 (2010).
79. Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin. Oncol. 37(5), 508-516 (2010).
80. Qin L, Guan HG, Zhou XJ, Yin J, Lan J, Qian HX. Blockade of 4-1BB/4-1BB ligand interactions prevents acute rejection in rat liver transplantation. Chin. Med. J. (Engl.) 123(2), 212-215 (2010).
81. Coyle PK. The role of natalizumab in the treatment of multiple sclerosis. Am. J. Manag. Care 16(6 Suppl.), S164-S170 (2010).
82. Evans R, Patzak I, Svensson L et al. Integrins in immunity. J. Cell Sci. 122(Pt 2), 215-225 (2009).
83. Stengel FM, Petri V, Campbell GA et al. Control of moderate-to-severe plaque psoriasis with efalizumab: 24-week, open-label, Phase IIIb/IV Latin American study results. Arch. Drug Inf. 2(4), 71-78 (2009).
84. Yacyshyn B, Chey WY, Wedel MK, Yu RZ, Paul D, Chuang E. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin. Gastroenterol. Hepatol. 5(2), 215-220 (2007). (Pubitemid 46216935)
85. del Zoppo GJ. Acute anti-inflammatory approaches to ischemic stroke. Ann. NY Acad. Sci. 1207, 143-148 (2010).
86. Paul LC, Davidoff A, Benediktsson H, Issekutz T. Anti-integrin (LFA-1, VLA-4, and Mac-1) antibody treatment and acute cardiac graft rejection in the rat. Transpl. Int. 9(4), 420-425 (1996). (Pubitemid 26229586)
87. Larsen CP, Ritchie SC, Hendrix R et al. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J. Immunol. 152(11), 5208-5219 (1994).
88. Vincenti F. Costimulation blockade in autoimmunity and transplantation. J. Allergy Clin. Immunol. 121(2), 299-306; quiz 307-298 (2008). (Pubitemid 351215188)
89. Larsen CP, Pearson TC, Adams AB et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA-4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5(3), 443-453 (2005). (Pubitemid 40313335)
90. Ansari MJ, Salama AD, Chitnis T et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 198(1), 63-69 (2003). (Pubitemid 36870186)
91. Folkl A, Bienzle D. Structure and function of programmed death (PD) molecules. Vet. Immunol. Immunopathol. 134(1-2), 33-38 (2010).
92. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11(11), 3887-3895 (1992).
93. Agata Y, Kawasaki A, Nishimura H et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8(5), 765-772 (1996). (Pubitemid 26148299)
94. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192(7), 1027-1034 (2000).
95. Latchman Y, Wood CR, Chernova T et al. PDL-2 is a second ligand for PD-1 and inhibits T-cell activation. Nat. Immunol. 2(3), 261-268 (2001). (Pubitemid 33706004)
96. Nurieva RI, Liu X, Dong C. Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol. Rev. 229(1), 88-100 (2009).
97. Sharpe A. Costimulation and regulation of autoimmunity and tolerance. J. Pediatr. Gastroenterol. Nutr. 40(Suppl. 1), S20-S21 (2005). (Pubitemid 40478396)
98. Dong C, Juedes AE, Temann UA et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 409(6816), 97-101 (2001). (Pubitemid 32098632)
99. Ansari MJ, Fiorina P, Dada S et al. Role of ICOS pathway in autoimmune and alloimmune responses in NOD mice. Clin. Immunol. 126(2), 140-147 (2008).
100. Derre L, Rivals JP, Jandus C et al. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J. Clin. Invest. 120(1), 157-167 (2010).
101. Simnick AJ, Valencia CA, Liu R, Chilkoti A. Morphing low-affinity ligands into high-avidity nanoparticles by thermally triggered self-assembly of a genetically encoded polymer. ACS Nano. 4(4), 2217-2227 (2010).
102. Salmaso C, Olive D, Pesce G, Bagnasco M. Costimulatory molecules and autoimmune thyroid diseases. Autoimmunity 35(3), 159-167 (2002). (Pubitemid 34678736)
103. Brandt M, Grotkop C, Steinmann J, Steinhoff G. Prevention of lung allograft rejection by combined treatment with adhesion molecule antibodies and cyclosporine. Interact. Cardiovasc. Thorac. Surg. 2(4), 509-513 (2003). (Pubitemid 38112795)
104. Dedrick RL, Garovoy M. Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody. Transpl. Immunol. 9, 181-186 (2002).
105. Vincenti F, Pescovitz M, Rajagopalan PR et al. A Phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am. J. Transplant. 7, 1770-1777 (2007). (Pubitemid 46905435)
106. Oberholzer J, Kinzer K, Fiorina P. The anti-LFA-1 trial in islet transplantation. Am. J. Transplant. 10(8), 1725-1726 (2010).
107. Posselt AM, Bellin MD, Tavakol M et al. Islet transplantation in Type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am. J. Transplant. 10(8), 1870-1880 (2010).
108. Dustin ML, Tseng SY, Varma R, Campi G. T cell-dendritic cell immunological synapses. Curr. Opin. Immunol. 18(4), 512-516 (2006). (Pubitemid 43947585)
109. Yokosuka T, Saito T. Dynamic regulation of T-cell costimulation through TCR-CD28 microclusters. Immunol. Rev. 229(1), 27-40 (2009).
110. Saito T, Yokosuka T, Hashimoto-Tane A. Dynamic regulation of T-cell activation and co-stimulation through TCR-microclusters. FEBS Lett. 584(24), 4865-4871 (2010).
111. Wulfing C, Davis MM. A receptor/ cytoskeletal movement triggered by costimulation during T-cell activation. Science 282(5397), 2266-2269 (1998). (Pubitemid 29004077)
112. Saito T, Yokosuka T. Immunological synapse and microclusters: the site for recognition and activation of T cells. Curr. Opin. Immunol. 18(3), 305-313 (2006).
113. Valitutti S, Muller S, Cella M, Padovan E, Lanzavecchia A. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 375(6527), 148-151 (1995).
114. Bromley SK, Burack WR, Johnson KG et al. The immunological synapse. Annu. Rev. Immunol. 19, 375-396 (2001). (Pubitemid 32368040)
115. Mempel TR, Henrickson SE, Von Andrian UH. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427(6970), 154-159 (2004). (Pubitemid 38094955)
116. Rodriguez-Fernandez JL, Riol-Blanco L, Delgado-Martin C. What is the function of the dendritic cell side of the immunological synapse? Sci. Signal. 3(105), re2 (2010).
117. Grakoui A, Bromley SK, Sumen C et al. The immunological synapse: a molecular machine controlling T-cell activation. Science 285(5425), 221-227 (1999). (Pubitemid 29329988)
118. Jo EK, Wang H, Rudd CE. An essential role for SKAP-55 in LFA-1 clustering on T cells that cannot be substituted by SKAP-55R. J. Exp. Med. 201(11), 1733-1739 (2005). (Pubitemid 41002892)
119. Dustin ML. Modular design of immunological synapses and kinapses. Cold Spring Harb. Perspect. Biol. 1(1), a002873 (2009).
120. Teft WA, Madrenas J. The immunological synapse as a novel therapeutic target. Curr. Opin. Investig. Drugs 7(11), 1008-1013 (2006). (Pubitemid 44756128)
121. Hartman NC, Nye JA, Groves JT. Cluster size regulates protein sorting in the immunological synapse. Proc. Natl Acad. Sci. USA 106(31), 12729-12734 (2009).
122. Dustin ML, Chakraborty AK, Shaw AS. Understanding the structure and function of the immunological synapse. Cold Spring Harb. Perspect. Biol. 2(10), a002311 (2010).
123. Dustin ML, Cooper JA. The immunological synapse and the actin cytoskeleton: molecular hardware for T cell signaling. Nat. Immunol. 1(1), 23-29 (2000).
124. Krummel M, Wulfing C, Sumen C, Davis MM. Thirty-six views of T-cell recognition. Philos. Trans. R Soc. Lond. B Biol. Sci. 355(1400), 1071-1076 (2000).
125. Varma R, Campi G, Yokosuka T, Saito T, Dustin ML. T cell receptor-proximal signals are sustained in peripheral microclusters and terminated in the central supramolecular activation cluster. Immunity 25(1), 117-127 (2006). (Pubitemid 44066825)
126. Lebedeva T, Dustin ML, Sykulev Y. ICAM-1 co-stimulates target cells to facilitate antigen presentation. Curr. Opin. Immunol. 17(3), 251-258 (2005). (Pubitemid 40692659)
127. Bhatia S, Edidin M, Almo SC, Nathenson SG. B7-1 and B7-2: similar costimulatory ligands with different biochemical, oligomeric and signaling properties. Immunol. Lett. 104(1-2), 70-75 (2006). (Pubitemid 43330711)
128. Kiessling LL, Strong LE. Synthetic multivalent ligands as probes of signal transduction. Angew. Chem. Int. Ed. Engl. 45, 2348-2368 (2006). (Pubitemid 44105109)
129. Ev CMR. Targeting drugs to combinations of receptors: a modeling analysis of potential specificity. Ann. Biomed. Eng. 33, 1113-1124 (2005).
130. Johnson RN, Kopecek J Synthesis and evaluation of multivalent branched HPMA copolymer-Fab' conjugates targeted to the B-cell antigen CD20. Bioconjug. Chem. 20, 129-137 (2009).
131. Puffer EB, Hollenbeck JJ, Kink JA, Kiessling LL. Activating B cell signaling with defined multivalent ligands. ACS Chem. Biol. 2, 252-262 (2007). (Pubitemid 47629213)
132. Muro S, Qiu W, Leferovich J, Cui X, Berk E, Muzykantov VR. Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1. J. Pharmacol. Exp. Ther. 317, 1161-1169 (2006). (Pubitemid 43764121)
133. Muro S, Thomas A, Koniaris L, Albelda SM, Muzykantov VR, Koval M A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J. Cell Sci. 116, 1599-1609 (2003). (Pubitemid 36527505)
134. Symer DE, Diamond DJ, Dintzis HM. Inhibition or activation of human T cell receptor transfectants is controlled by defined, soluble antigen arrays. J. Exp. Med. 176, 1421-1430 (1992).
135. Schneck JP, O'Herrin SM, Greten TF. Monitoring antigen-specific T cells using MHC-Ig dimers. Curr. Protoc. Immunol. 17(17) 12 (2001).
136. Wong RL, Zhu X, You L et al. Interleukin-15:interleukin-15 receptor {a} scaffold for creation of multivalent targeted immune molecules. Protein Eng. Des. Sel. 24(4), 373-383 (2010).
137. Mallikaratchy PR, Gardner JR, Kuryavyi V et al. A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia. Nucleic Acids Res. 39(6), 2458-2469 (2010).
138. Greene JL, Emswiler J, Peach R, Bajorath J, Cosand W, Linsley PS. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J. Biol. Chem. 43, 26762-26771 (1996). (Pubitemid 26359085)
139. Park CG, Lee KM, Szot GL, Bluestone JA, Lee KD. Targeting and blocking B7 costimulatory molecules on antigen-presenting cells using CTLA-4-Ig-conjugated liposomes: in vitro characterization and in vivo factors affecting biodistribution. Pharm. Res. 20, 1239-1248 (2003). (Pubitemid 36951849)
140. Dustin ML, Springer TA. Correlation of CD2 binding and functional properties of multimeric and monomeric lymphocyte function-associated antigen 3. J. Exp. Med. 169, 503-517 (1989). (Pubitemid 19050647)
141. Jin ZH, Waki A, Akaji K, Coll JL, Saga T, Fujibayashi Y. Effect of multimerization of a linear Arg-Gly-Asp peptide on integrin binding affinity and specificity. Biol. Pharm. Bull. 33, 370-378 (2010).
142. Voulgaraki D, Letarte M, Foster-Cuevas M, Brown MH, Barclay AN. Multivalent recombinant proteins for probing functions of leucocyte surface proteins such as the CD200 receptor. Immunology 115, 337-346 (2005). (Pubitemid 40896032)
143. Hong S, Leroueil PR, Majoros IJ, Orr BG, Baker JR Jr, Banaszak Holl MM. The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem. Biol. 14(1), 107-115 (2007). (Pubitemid 46124068)
144. Stukel JM, Li RC, Maynard HD, Caplan MR. Two-step synthesis of multivalent cancer-targeting constructs. Biomacromolecules 11(1), 160-167 (2010).
145. Farokhzad OC, Cheng J, Teply BA et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl Acad. Sci. USA 103(16), 6315-6320 (2006).
146. Johnson RN, Kopeckova P, Kopecek J. Synthesis and evaluation of multivalent branched HPMA copolymer-Fab' conjugates targeted to the B-cell antigen CD20. Bioconjug. Chem. 20(1), 129-137 (2009).
147. Meng H, Chen JY, Mi L et al. Conjugates of folic acids with BSA-coated quantum dots for cancer cell targeting and imaging by single-photon and two-photon excitation. J. Biol. Inorg. Chem. 16(1), 117-123 (2011).
148. Han HD, Mangala LS, Lee JW et al. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin. Cancer Res. 16(15), 3910-3922 (2010).
149. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9(8), 615-627 (2010).
150. Carlson CB, Mowery P, Owen RM, Dykhuizen EC, Kiessling LL. Selective tumor cell targeting using low-affinity, multivalent interactions. ACS Chem. Biol. 2(2), 119-127 (2007). (Pubitemid 47490233)
151. Shewmake TA, Solis FJ, Gillies RJ, Caplan MR. Effects of linker length and flexibility on multivalent targeting. Biomacromolecules 9(11), 3057-3064 (2008).
152. Kim M, Carman CV, Yang W, Salas A, Springer TA. The primacy of affinity over clustering in regulation of adhesiveness of the integrin {a}L{b}2. J. Cell Biol. 167(6), 1241-1253 (2004). (Pubitemid 40066637)
153. Hogg N, Laschinger M, Shimaoka M, Springer TA. Therapeutic antagonists and conformational regulation of integrin function. Nat. Rev. Drug Discov. 2(9), 703-716 (2003). (Pubitemid 37361786)
154. Shimaoka M, Springer TA. Therapeutic antagonists and conformational regulation of integrin function. Nat. Rev. Drug Discov. 2(9), 703-716 (2003). (Pubitemid 37361786)
155. Charles CH, Kohlstaedt LA, Morantte IG et al. Prevention of human rhinovirus infection by multivalent fab molecules directed against ICAM-1. Antimicrob. Agents Chemother. 47, 1503-1508 (2003). (Pubitemid 36548529)
156. Gestwicki JE, Strong LE, Oetjen KA, Kiessling LL. Influencing receptor-ligand binding mechanisms with multivalent ligand architecture. J. Am. Chem. Soc. 124, 14922-14933 (2002). (Pubitemid 36014100)
157. Lebedeva T, Dustin ML, Sykulev Y. ICAM-1 co-stimulates target cells to facilitate antigen presentation. Curr. Opin. Immunol. 17, 251-258 (2005). (Pubitemid 40692659)
158. Hogg N, Bates PA, Stanley P, Randi AM. The sticking point: how integrins bind to their ligands. Trends Cell Biol. 4, 379-382 (1994). (Pubitemid 24314989)
159. Chittasupho C, Krise JP, Siahaan TJ, Berkland C. cIBR effectively targets nanoparticles to LFA-1 on acute lymphoblastic T cells. Mol. Pharm. 7, 146-155 (2010).
160. Zhang N, Duangrat C, Siahaan TJ, Berkland C. PLGA nanoparticle-peptide conjugate effectively targets intercellular cell-adhesion molecule-1. Bioconjug. Chem. 19, 145-152 (2008). (Pubitemid 351213845)
161. Chittasupho C, Baoum A, Yakovleva T, Siahaan TJ, Berkland CJ. ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. Eur. J. Pharm. Sci. 37, 141-150 (2009).
162. Muro S, Gajewski C, Koval M, Muzykantov VR. ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs. Blood 105(2), 650-658 (2005). (Pubitemid 40070749)
163. Fakhari A, Baoum A, Siahaan TJ, Le KB, Berkland C. Controlling ligand surface density optimizes nanoparticle binding to ICAM-1. J. Pharm. Sci. 100(3), 1045-1056 (2011).
164. Chittasupho C, Shannon L, Siahaan TJ, Vines CM, Berkland C. Nanoparticles targeting dendritic cell surface molecules effectively block T cell conjugation and shift response. ACS Nano. 5(3), 1693-1702 (2011).